According to Ardelyx's latest financial reports the company's current revenue (TTM) is $0.12 B. In 2022 the company made a revenue of $52.15 M an increase over the years 2021 revenue that were of $10.09 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.12 B | 138.61% |
2022 | $52.15 M | 416.57% |
2021 | $10.09 M | 33.36% |
2020 | $7.57 M | 43.36% |
2019 | $5.28 M | 102.57% |
2018 | $2.6 M | -93.79% |
2017 | $42 M | |
2016 | N/A | -100% |
2015 | $24.02 M | -24.03% |
2014 | $31.62 M | 9.32% |
2013 | $28.92 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $40.10 B | 32,127.45% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 22,550.58% | ๐บ๐ธ USA |
Sanofi SNY | $50.35 B | 40,364.03% | ๐ซ๐ท France |
AstraZeneca AZN | $45.81 B | 36,708.99% | ๐ฌ๐ง UK |
OPKO Health
OPK | $0.86 B | 593.81% | ๐บ๐ธ USA |